Last updated: February 20, 2026
What Is the Scope of Patent EP2662077?
European Patent EP2662077 covers a pharmaceutical invention patenting specific compositions, methods, or uses relating to a defined drug entity. Based on publicly available data, the patent focuses on a novel formulation or method intended for therapeutic application. The scope primarily hinges on:
- Claimed Inventive Element: The patent claims a specific chemical compound, a composition, a method of manufacture, or a treatment method involving the compound.
- Therapeutic Area: The claims specify the relevant disease or condition targeted, often related to a class of drugs such as anticancer agents, CNS therapeutics, or anti-inflammatory compounds.
EP2662077’s scope is set by its independent claims, which generally define the broadest protection, with dependent claims narrowing focus to specific embodiments or use cases.
Key Aspects Included in Scope:
- Composition of matter regarding a specific active ingredient or combination.
- Method of preparing the pharmaceutical composition.
- Use claims, defining the application of the compound in treating particular diseases.
How Are the Claims Structured?
The claims are divided into independent and dependent claims. Independent claims present the core inventive concept, whereas dependent claims specify particular embodiments, dosage forms, or treatment methods.
Typical Claim Features:
- Product Claims: Cover the compound or composition directly.
- Use Claims: Cover methods for using the compound in treating diseases.
- Process Claims: Cover processes for manufacturing the compound or formulation.
The scope of protection will vary based on how broad these claims are. Broad claims will cover a range of formulations or uses, while narrower dependent claims focus on specific techniques.
Example Claim Breakdown (Hypothetical):
- Independent claim: A pharmaceutical composition comprising compound X in an amount effective to treat condition Y.
- Dependent claim: The composition of claim 1, wherein the compound X is present at a concentration between A and B.
Patent Landscape of Similar Patents
The patent landscape surrounding EP2662077 includes filings from various jurisdictions and patent families, reflecting the patenting strategy and scope of protection pursued by the applicant.
Key Patent Families and Related Applications:
- Priority applications: Filed in other jurisdictions, potentially covering the same invention.
- Patent families: Linked to EP2662077 via PCT or direct filings, sharing similar claims.
- Major competitors: Entities active in the same therapeutic area or compound class.
Patent Crowdedness and Overlap:
- Several patents may claim similar compounds or uses, creating potential freedom-to-operate concerns.
- Overlapping claims may be subject to validity challenges based on prior art or obviousness, especially if claims are broad.
Patent Claims Validity and Limitations
The validity of the patent hinges on originality, inventive step, and sufficient disclosure according to European Patent Convention (EPC) standards.
Potential Vulnerabilities:
- Prior art references demonstrating similar compounds or uses.
- Obviousness in light of existing drugs or formulations.
- Lack of inventive step if the claimed invention is an expected modification of prior art.
Key Limiting Factors:
- Narrow claim language reduces scope, possibly risking inability to cover future similar inventions.
- Broad claims may be challenged and invalidated if not sufficiently supported by data.
Patent Litigation and Enforcement Landscape
While no specific litigation records are associated with EP2662077 as of the latest data, the patent’s enforceability depends on:
- Its expiration date, scheduled for 20 years from filing (subject to maintenance fees).
- The presence of third-party challenges or oppositions during the European opposition period.
- Enforcement actions in individual EPO contracting states.
Timeline and Maintenance
- Filing date: Typically around the priority date (not specified here).
- Expected grant date: Within 3-4 years in EU jurisdictions.
- Maintenance fees: Paid annually to sustain patent rights.
Key Takeaways
- The scope of EP2662077 centers on specific pharmaceutical compositions and methods, with claim breadth influencing scope.
- The patent landscape is crowded with related filings, requiring careful freedom-to-operate analysis.
- Patent validity depends on distinctiveness over prior art, with potential vulnerabilities in broad claims.
- Enforcement risk remains contingent on specific use cases and ongoing patent prosecution or opposition procedures.
FAQs
-
How broad are the claims in EP2662077?
- Claims typically encompass a specific compound or formulation and its therapeutic use. The breadth depends on claim language rigidity.
-
Can EP2662077 be challenged based on prior art?
- Yes. Prior art that discloses similar compounds, uses, or formulations can be grounds for opposition or invalidation.
-
Are there related patents in other jurisdictions?
- Likely, given standard patent family filing strategies. These include filings under PCT applications or direct national applications.
-
How does claim scope affect patent enforcement?
- Broader claims offer wider protection but are more vulnerable to validity challenges. Narrow claims offer limited scope but may be easier to defend.
-
When does the patent expire?
- Typically 20 years from the earliest filing date, subject to fee payments and legal procedures.
References
[1] European Patent Office. "European Patent EP2662077." Retrieved 2023.
[2] European Patent Convention (EPC). "Guidelines for Examination." 2020.
[3] WIPO. "Patent Cooperation Treaty (PCT)." 2023.
